featured
Lenalidomide Maintenance After First-Line Therapy for High-Risk Chronic Lymphocytic Leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lenalidomide Maintenance After First-Line Therapy for High-Risk Chronic Lymphocytic Leukaemia (CLLM1): Final Results From a Randomised, Double-Blind, Phase 3 Study
Lancet Haematol 2017 Sep 12;[EPub Ahead of Print], AM Fink, J Bahlo, S Robrecht, O Al-Sawaf, A Aldaoud, H Hebart, K Jentsch-Ullrich, S Dörfel, K Fischer, CM Wendtner, T Nösslinger, P Ghia, F Bosch, AP Kater, H Döhner, M Kneba, KA Kreuzer, E Tausch, S Stilgenbauer, M Ritgen, S Böttcher, B Eichhorst, M HallekFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.